Apelin
- Category
- Muscle & Performance
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A naturally occurring peptide studied for cardiovascular and kidney effects, marketed by some clinics for anti-aging and muscle recovery. Human evidence supports blood pressure and blood flow effects, but anti-aging and muscle claims rest on animal and mechanistic work only. Its short half-life limits use, and liver enzyme elevations with the investigational small-molecule agonist azelaprag, preclinical tumor-angiogenesis findings, and blood-pressure effects remain concerns; these findings do not establish native apelin hepatotoxicity. Not FDA-approved; available mainly as unregulated products sold online.
Read Full recordStudied uses & evidence
Studied uses(6)
Cardiovascular protection: vasodilation, increased cardiac output, and blood pressure reduction
MediumHuman infusion trials show blood pressure and cardiac output shifts, not proven long-term protection.
Anti-aging and sarcopenia reversal via exerkine-mediated muscle regeneration
LowMuscle regeneration shown in aged mice; human peptide evidence is lacking, correlational only.
Pulmonary vascular improvement and reduced pulmonary vascular resistance in PAH
HighRandomized trial in PAH patients showed reduced pulmonary vascular resistance from a single infusion.
Evidence limits
- Evidence Level
- Moderate
Apelin's clinical evidence base is moderate-to-strong for acute cardiovascular hemodynamic effects and growing for renal and metabolic endpoints. The strongest human data come from Japp et al. 2010 (Circulation), an RCT demonstrating vasodilation and increased cardiac output in heart failure patients and healthy volunteers; Brash et al. 2018 (JACC), a double-blind crossover RCT in 19 PAH patients showing reduced pulmonary vascular resistance; Chapman et al. 2024 (Nature Communications), a double-blind RCT in 12 CKD patients that found short-term renal changes; and Gourdy et al. 2018, in which apelin improved insulin sensitivity in overweight men. For drug development, the AMG 986 first-in-human study (182 subjects, Cardiovascular Drugs and Therapy 2022) showed acceptable safety up to 650 mg/day. It produced no clinically meaningful hemodynamic effects in heart failure patients. Azelaprag (BGE-105) Phase 2 was discontinued in December 2024 due to hepatotoxicity signals. The major gaps are that no completed human trials target aging or longevity endpoints, that all native apelin infusion studies are acute (minutes to hours) with no chronic dosing data in humans, and that no apelin-targeting therapy has reached Phase 3.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
HighApelin promotes tumor angiogenesis, cancer cell proliferation, metastasis, and suppresses apoptosis across multiple cancer types.
Hypotension
ModerateApelin causes vasodilation and reduces systemic blood pressure. Use caution in hypotensive states.
General cautions
Pregnancy
AbsoluteNo reproductive safety data. Apelin/APJ axis plays roles in placentation.
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
Extremely short plasma half-life limiting therapeutic utility
HighPotential hepatotoxicity with synthetic apelin receptor agonists
ModeratePotential pro-tumorigenic effects via angiogenesis promotion
ModerateHypotension risk with acute administration
ModerateInteraction with fluid balance and vasopressin regulation
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.